High throughput approach for generating human monoclonal antibodies

产生人单克隆抗体的高通量方法

• 批准号: 8904621
• 负责人: Hiep T Tran
• 金额: $ 22.48万
• 依托单位: ABZYME THERAPEUTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8904621
• 关键词: Affinity; Animals; Antibodies; Antibody Formation; Autoantigens; Binding; Biological Assay; Biological Models; Cell surface; Cells; Cholesterol; DNA; Development; Diagnosis; Diploidy; Engineering; Enzyme-Linked Immunosorbent Assay; Enzymes; Evolution; Fluorescence-Activated Cell Sorting; Galactose; Generations; Genes; Genetic Models; Human; IL2RA gene; Immunization; Immunoassay; Immunoglobulin Somatic Hypermutation; In Vitro; Individual; Interstitial Collagenase; Libraries; Light; Malignant Neoplasms; Mammalian Cell; Measures; Medical; Methodology; Monoclonal Antibodies; National Institute of General Medical Sciences; Nature; Partner in relationship; Petromyzon marinus; Phase; Process; Productivity; Proteins; Reagent; Regulatory T-Lymphocyte; Research; Rheumatoid Arthritis; Saccharomyces cerevisiae; Sensitivity and Specificity; Specificity; Surface; Surface Plasmon Resonance; System; Therapeutic; Therapeutic antibodies; Time; TimeLine; Toxin; Yeasts; activation-induced cytidine deaminase; analog; base; cross reactivity; density; disulfide bond; expression vector; human disease; human monoclonal antibodies; immunogenic; improved; in vivo; innovation; interest; novel; pathogen; public health relevance; response; screening; small molecule; success; therapeutic target

 DESCRIPTION (provided by applicant): Thanks to their exquisite specificity and sensitivity, monoclonal antibodies (Mab) have found a broad application in research, diagnosis and therapy. For treatment of human diseases, fully human antibodies are the most desirable as they are generally not immunogenic and well-tolerated. While there are several existing approaches for generation of antibodies, the processes are still time-consuming, labor-intensive, and unpredictable of success. To simplify and to accelerate the generation of fully human antibodies, a novel non-animal approach for antibody production is proposed. The objective will be achieved by using a Self-Diversifying Human Antibody Library (SHALib) effectively displayed on yeast cell surface. SHALib will provide a diverse array of antibodies in vitro, without the need of animal immunization and potential necessary humanization of the antibody. Starting from a naive antibody library from healthy human donors, antibodies with high-affinity and specificity to various targets will be generated and selected through repeated rounds of systematic evolution by somatic hypermutation, target-specific enrichment and fluorescence-activated cell sorting. Since this is a non-animal system, the platform can generate human antibodies against toxins, pathogens, self-antigens, and the like which are by nature difficult to obtain. As a proof-of-principle, in phase I, we will develop human antibodies to five selected targets of therapeutic importance. The targets are for the treatment of high cholesterol (PCSK9), rheumatoid arthritis (MMP1 and MMP13) and cancer (MMP7 and regulatory T cell protein CD25). In Phase II, the platform will be used to develop human monoclonal antibodies to at least 50 targets that are involved in different human diseases. The platform will allow generating quickly human monoclonal antibodies that are of therapeutic potential.

 描述（申请人提供）：单克隆抗体（Mab）凭借其精湛的特异性和敏感性，在研究、诊断和治疗中得到了广泛的应用。对于人类疾病的治疗，全人抗体是最理想的，因为它们通常不是。虽然有几种现有的抗体生成方法，但这些过程仍然耗时、费力且成功率难以预测。动物方法该目标将通过使用有效展示在酵母细胞表面的自我多样化人类抗体库（SHALib）来实现，SHALib 将在体外提供多种抗体。 从健康人类捐赠者的天然抗体库开始，通过体细胞超突变、靶点特异性的反复系统进化，将产生和选择对各种靶点具有高亲和力和特异性的抗体。由于这是一个非动物系统，该平台可以产生针对本质上难以获得的毒素、病原体、自身抗原等的人类抗体。在第一阶段的原理验证中，我们将针对五个选定的具有治疗重要性的靶标开发人类抗体，这些靶标用于治疗高胆固醇（PCSK9）、类风湿性关节炎（MMP1 和 MMP13）和癌症（MMP7 和调节性 T）。在第二阶段，该平台将用于开发针对涉及不同人类疾病的至少 50 个靶标的人类单克隆抗体。的治疗潜力。